Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Rani Therapeutics Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Rani Therapeutics Holdings, Inc.’s stock price such as:

• Rani Therapeutics Holdings, Inc.’s current stock price and volume
• Why Rani Therapeutics Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for RANI from analysts
• RANI’s stock price momentum as measured by its relative strength

About Rani Therapeutics Holdings, Inc. (RANI)

Before we jump into Rani Therapeutics Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Want to learn more about Rani Therapeutics Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Rani Therapeutics Holdings, Inc..

Rani Therapeutics Holdings, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Rani Therapeutics Holdings, Inc.’s stock price was $1.600.

Rani Therapeutics Holdings, Inc. is down 1.23% from its previous closing price of $1.620.

During the last market session, Rani Therapeutics Holdings, Inc.’s stock traded between $1.560 and $1.640. Currently, there are approximately 46.44 million shares outstanding for Rani Therapeutics Holdings, Inc..

Rani Therapeutics Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Rani Therapeutics Holdings, Inc. Stock Price History

Rani Therapeutics Holdings, Inc.’s (RANI) price is currently down 27.27% so far this month.

During the month of November, Rani Therapeutics Holdings, Inc.’s stock price has reached a high of $2.630 and a low of $1.460.

Over the last year, Rani Therapeutics Holdings, Inc. has hit prices as high as $3.870 and as low as $0.387. Year to date, Rani Therapeutics Holdings, Inc.’s stock is up 16.79%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Rani Therapeutics Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there was 1 analyst who downgraded Rani Therapeutics Holdings, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Rani Therapeutics Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Rani Therapeutics Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Rani Therapeutics Holdings, Inc. (RANI) by visiting AAII Stock Evaluator.

Relative Price Strength of Rani Therapeutics Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Rani Therapeutics Holdings, Inc. has a weighted four-quarter relative price strength of 59.40%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Rani Therapeutics Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Rani Therapeutics Holdings, Inc. Stock Price: Bottom Line

As of November 28, 2025, Rani Therapeutics Holdings, Inc.’s stock price is $1.600, which is down 1.23% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Rani Therapeutics Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.